Full-Time

Manager – External Partnerships

Onehub

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$109.5k - $208.5k/yr

+ Long-term incentive program

North Chicago, IL, USA

Hybrid

Bachelor's

Category
Business & Strategy (1)
Required Skills
Data Analysis

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 6 years of experience in vendor management, consulting, contracting, pricing, procurement, external partnerships, patient services, access support, or related commercial operations is required.
  • Demonstrated program management experience, including managing multiple concurrent projects, project planning, and financial or budget schedule tracking, is required.
  • Proven ability in cross-functional leadership and driving alignment across diverse stakeholder groups in a matrixed organization is required.
  • Excellent stakeholder communication skills, including the ability to create executive-level updates, program dashboards, and status reports, are required.
Responsibilities
  • Provide oversight for OneHUB vendors supporting AbbVie's Access and Affordability programs across OneHUB and AbbVie Patient Services.
  • Manage day-to-day vendor oversight, including service-level agreements, quality standards, compliance requirements, and evolving business needs.
  • Catalog service-level agreements and metrics across vendors to identify standardization opportunities.
  • Partner with AbbVie Patient Services and brand stakeholders to translate strategic priorities into operational execution.
  • Identify cross-vendor performance enhancement opportunities to optimize patient experience, efficiency, and program effectiveness.
  • Participate in requests for proposals, contract redlining, contract negotiations, and pricing discussions.
  • Evaluate proposals and create pricing simulations that meet business objectives.
  • Create a blueprint for the external partnership vertical, including current vendors, contracts, and renewal cycles.
  • Establish ways of working with stakeholders and create a governance model.
  • Drive multiple concurrent vendor and patient services initiatives from planning through execution, ensuring on-time delivery, budget adherence, and stakeholder communication.
  • Oversee hub vendor performance across multiple partners.
  • Ensure adherence to contractual obligations, service-level agreements, key performance indicators, quality standards, and compliance requirements.
  • Develop and maintain governance frameworks, reporting structures, and performance review cadences.
  • Conduct business reviews with external hub vendors.
  • Identify performance gaps and direct corrective action plans with clear accountability and measurable outcomes.
  • Define the scope of requests for proposals and work with category management to translate requirements and drive the process.
  • Create guidance for proposal scoring, prepare for oral presentations, and organize vendor site visits.
  • Lead cross-functional efforts to align Patient Services, Brand, Information Technology, and Compliance teams around vendor performance goals and program milestones.
  • Track open action items, escalate blockers, and ensure accountability across vendor and internal stakeholder teams.
  • Monitor vendor financial performance and resource utilization.
  • Maintain budget and financial schedule tracking for vendor programs, monitor spend against planned budgets, and flag variances for resolution.
  • Identify operational, compliance, and performance risks and implement mitigation strategies.
  • Apply structured risk mitigation planning to surface, assess, and address vendor operational and compliance risks before they affect patient services.
  • Ensure adherence to regulatory and quality standards within patient support operations.
  • Analyze existing vendor programs to identify opportunities and economies of scale that produce financial savings.
  • Analyze request-for-proposal pricing and create price simulations for contract negotiations.
  • Partner with AbbVie Patient Services to understand evolving strategy, patient support models, and brand needs.
  • Translate new product launches, lifecycle changes, and access model updates into operational direction for vendors.
  • Provide performance updates, risk assessments, and strategic recommendations to internal stakeholders.
  • Maintain stakeholder communication through structured reporting, status updates, and executive-level briefings.
  • Ensure vendor capabilities and resource models scale to meet changing business demands.
  • Create clear ways of working with internal stakeholders.
  • Identify opportunities to enhance performance, improve efficiency, and standardize best practices across vendors.
  • Use data and insights to compare performance trends and identify scalable improvement opportunities.
  • Guide vendors on process enhancements, staffing adjustments, workflow redesign, and technology optimization.
  • Drive root cause analysis and mitigation planning for systemic or recurring issues.
  • Apply project planning discipline to vendor improvement initiatives by defining scope, timelines, owners, and success metrics.
  • Lead and develop a team responsible for external vendor relationship management and performance monitoring.
  • Set priorities, accountability standards, and performance expectations.
  • Coach team members to improve vendor management capabilities, analytical rigor, and operational effectiveness.
  • Synthesize vendor data to extract meaningful insights.
  • Manage multiple concurrent projects across the vendor portfolio with clear project plans, milestones, and resource assignments.
  • Organize competing projects and create artifacts defining project scope, scale, and value for internal and external stakeholders.
  • Develop and maintain program schedules and financial tracking tools to monitor progress, budget spend, and resource utilization.
  • Create repositories of vendors and contracts with their service-level agreements, metrics, quality targets, and training targets.
  • Create a quarterly-objective program roadmap for external partnerships.
Desired Qualifications
  • Experience in healthcare, biopharma, patient services, specialty pharmacy, or access support environments is preferred.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.